BRIDGEBIO PHARMA INC (BBIO)       9.94  -0.26 (-2.55%)

9.94  -0.26 (-2.55%)

US10806X1028 - Common Stock - After market: 9.91 -0.03 (-0.3%)

Buy % Consensus

86
Analysts have set a mean price target of 24.93. This target is 150.84% above the current price.
BBIO was analyzed by 16 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about BBIO.
In the previous month the buy percentage consensus was at a similar level.
BBIO was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target

Price Low Median Mean High 9.9417.1723.4624.9333.60 - 72.74% 136.02% 150.84% 238.03%

Up and Down Grades

Date Firm Action Rating
2022-08-24 Mizuho Maintains Buy
2022-07-26 SVB Leerink Maintains Outperform
2022-05-24 Goldman Sachs Maintains Buy
2022-05-06 SVB Leerink Maintains Outperform
2022-03-11 JP Morgan Maintains Overweight
2022-03-09 SVB Leerink Maintains Outperform
2022-03-04 SVB Leerink Maintains Outperform
2021-12-28 SVB Leerink Maintains Outperform
2021-12-28 HC Wainwright & Co. Maintains Buy
2021-11-19 SVB Leerink Maintains Outperform
2021-10-25 HC Wainwright & Co. Maintains Buy
2021-10-04 SVB Leerink Maintains Outperform
2021-09-10 B of A Securities Upgrade Neutral -> Buy
2021-08-06 SVB Leerink Maintains Outperform
2021-05-21 UBS Initiate Buy
2021-05-07 Goldman Sachs Maintains Buy
2021-03-23 SVB Leerink Maintains Outperform
2021-03-04 Mizuho Maintains Buy
2021-02-09 Goldman Sachs Reiterate Buy

Analyst Ratings Stock Screener Links

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA